Estrogen-related receptors in breast cancer and prostate cancer

Aya Misawa¹ and Satoshi Inoue¹,²*

¹ Department of Anti-Aging Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ² Division of Gene Regulation and Signal Transduction, Research Center for Genomic Medicine, Saitama Medical University, Saitama, Japan

Estrogen-signaling pathways are implicated in the development of breast cancer and prostate cancer. Various studies have focused on additional signaling pathways, mediated by estrogen-related receptors (ERRs). ERRs are constitutively active receptors that share a high degree of homology with the classical estrogen receptors (ERs). However, they do not bind to estrogen, while ERs do. ERRs are involved in the development of alternative pathways that lead to the development of cancer and are regarded as potential therapeutic targets for the treatment of breast cancer and prostate cancer that do not respond to conventional therapies. In this review, we first present general structural features of ERRs. Then, we focus on breast cancer and prostate cancer, which are primarily hormone-dependent cancers, and summarizes recent progress in elucidating the involvement of each ERR in these two types of malignancies.

Keywords: estrogen-related receptors, estrogen receptors, estrogen, androgen, breast cancer, prostate cancer

Introduction

Among the 48 members of the nuclear receptor superfamily, the estrogen receptor (ER)-like subfamily (NR3) is one of the seven subfamilies and is composed of three groups: ERs (NR3A), estrogen-related receptors (ERRs or NR3B), and 3-ketosteroid receptors (NR3C), which include the androgen receptor (AR), progesterone receptor (PR), glucocorticoid receptor (GR), and mineralocorticoid receptor (MR). ERRs were initially thought to share a common biological function with ERs, but unexpectedly, they do not bind to estrogen or endogenous ER ligands and are considered orphan nuclear receptors (1).

Estrogens are natural hormones considered to play a major role in promoting the proliferation of both the normal and neoplastic breast epithelium. Growing evidences suggest that estrogen-signaling pathways are implicated in not only the development of breast cancer but also in that of prostate cancer, which are both hormone-dependent cancers (2). ER-positive breast cancers are preferentially treated with antiestrogens such as selective ER modulators known as SERMs (including tamoxifen which is the most commonly used) or selective ER down-regulators known as SERDs (ICI 182,780) (3). Aromatase inhibitors are used in postmenopausal women to block the enzyme aromatase, which is involved in the final step of estrogen synthesis from circulating androgens (4). Androgen deprivation therapy (ADT) is used for the treatment of locally advanced, biochemically recurrent, and metastatic prostate cancer. However, after the initial response, these therapies for breast and prostate cancer fail and cancer will inevitably recur (5–7). The mechanisms underlying recurrence have not been fully clarified, but the acquisition of alternative intracellular ER signaling may be involved in hormonal therapy resistance.

Various studies have focused on additional estrogen-related signaling pathways, mediated by ERRs (8–10). Sequence analysis reveals that ERRs and the classical ERs share a high degree of...
homology within their DNA and ligand-binding domains (LBDs) (11). The ERR family consists of three closely related members: ERRα, ERRβ, and ERRγ (Figure 1). ERRs, like other nuclear receptors, consist of six conserved regions (A–F): A/B domain containing the N-terminal domain (NTD), C domain with a DNA binding domain (DBD), D domain, which corresponds to the hinge region, E domain containing a putative LBD, and the F domain or C-terminal region. The transcriptional activation function-1 (AF-1) site is located in the N-terminal A/B domain, and its activity does not depend on the presence of activating ligands. The ligand-regulated activation function-2 (AF-2) site is located at E domain and it is known to synergize with AF-1 to regulate gene expression (12, 13). These receptors are constitutively active due to the structure of the LBD that leaves the AF-2 exposed and capable of binding coregulators in the absence of ligand binding.

**ERR Action Mechanisms**

Like other nuclear receptors, the transcriptional activity of ERRs is dependent on the presence of coregulatory proteins, either corepressors or coactivators. Steroid receptor coactivator (SRC)-1, -2, and -3, which regulate hepatic metabolism, fat storage, and energy balance, have been shown to interact with one or more ERR isoform stimulating their transcriptional activity (14, 15). PPARγ coactivator (PGC)-1α and PGC-1β, which play essential roles in metabolic programs, have been shown to directly interact with ERRs, positively regulating the expression and activity of these nuclear receptors (16). The activity of the ERRs as transcription factors is generally inhibited through physical interaction with receptor interacting protein 140, RIP140, also known as nuclear receptor interacting protein 1, NRIP1, a corepressor that competes for interaction with PGC-1α for ERRs binding negatively regulating gene expression (17).

Estrogen-related receptors can bind to DNA on ERR response elements (ERREs) designated by the sequence 5′-TNAAGGTCA-3′ as well as the classical ER response elements (EREs) 5′-AGGTCANNNTGACCT-3′, where N represents any nucleotide (18–20). These orphan nuclear receptors play a central role in regulating cellular metabolism through the regulation of genes involved in glycolysis, oxidative phosphorylation, and tricarboxylic acid cycle (21). ERRα is present in tissues with high metabolism, such as the heart, kidney, intestinal tract, skeletal muscle, and brown adipose tissue (22). The expression of ERRβ and ERRγ is more restricted, being mainly expressed in the heart and kidney (22, 23). Both ERRα and ERRγ are upregulated in preadipocytes and pluripotent mesenchymal cells under adipogenic conditions, positively regulating lipid accumulation (24, 25). ERRβ and ERRγ are also expressed during the early embryonic development and in the central nervous system and spinal cord. Although ERRs have structural and functional similarities, mice deficient for each ERR exhibit different phenotypes, suggesting that these ERRs have specific and unique functions. ERRα-deficient mice are viable, but exhibit a phenotype characterized by reduced body weight, peripheral fat deposits, and resistance to high-fat diet-induced obesity (26). They also exhibit a loss of normal mitochondrial biogenesis (27). On the other hand, ERRβ-deficient mice are lethal due to impaired placenta formation (28). Interestingly, an important role of this orphan receptor in embryonic stem (ES) cells maintenance has been suggested,

---

**FIGURE 1** | Domain structure and protein length of ERRs and ERs. DBD, DNA binding domain; LBD, ligand-binding domain; AF-1, activating function-1; AF-2, activating function-2. The percentage conservation between ERRα and the other two ERRs is shown for each of the five domains.
as it is able to regulate self-renewal in ES cells in cooperation with octamer-binding protein 4, Oct4, and sex determining region Y-box 2, Sox2, replacing kruppel-like factor 4, Klf4, and consequently enhancing the transcription of reprogramming factors (29). ERRγ-deficient mice also die during the early postnatal period due to abnormal heart function (30). It has been reported that ERR overexpression increases glycolysis, while depletion results in the opposite effect, reducing aerobic glycolysis (31). Furthermore, ERRα and ERRγ were found to form heterodimers and bind to the promoters of the same target genes to regulate genes controlling both the glycolytic and the oxidative mitochondrial respiration phenotypes (32). These findings suggest that ERRs might contribute to a shift in cellular metabolism from normal mitochondrial oxidative phosphorylation to an aerobic glycolysis typical of cancer cells, known as the Warburg effect, increasing glucose consumption, and ATP production (33). However, a number of evidence suggest that ERRα and ERRγ have opposite functions in regulating cellular metabolism. ERRα could assist in setting a glycolytic profile required for the proliferation of rapidly dividing cells in normal tissues with high-energy demand and tumors consequently promoting cellular proliferation (34–39). By contrast, ERRγ high expression has been detected in tumors with better prognosis (36), and inhibition of this orphan receptor by a microRNA (miR-378*) induces a metabolic switch by promoting a Warburg-like phenotype (40). These findings illustrates the complexity of metabolic reprogramming by ERRs in cancer cells, where ERRα and ERRγ could cooperate or play an opposite role in the metabolic transcriptional pathway depending on the cellular environment and the expression of distinct coregulators (41) (Table 1).

**ERRs in Breast Cancer**

Breast cancer is the leading cause of cancer-related death in women worldwide (50). It is primarily a hormone-dependent disease that can be regulated by the status of steroid hormones such as estrogen and progesterone. Unfortunately, the emergence of hormone-resistant tumor cells after years of treatment is a major issue affecting patients with breast cancer (7). Breast cancers can be divided into five subtypes that vary in their treatment options and survival outcomes based on gene expression profiles (51–54). ERα positive (ERα+) and progesterone receptor positive (PR+) tumors account for approximately 70% of all cases (55, 56). These ERα+/PR+ tumors can be further classified into HER2+ and HER2– subtypes depending on epidermal growth factor receptor 2, ErbB-2, or HER2 gene expression. Blocking the estrogen production or estrogen binding to the receptor by tamoxifen or aromatase inhibitors is the standard treatment for both early and advanced ERα+ breast cancer (57, 58). For ERα negative (ERα−), progesterone receptor negative (PR−), and HER2+ (ERα−/PR−/HER2+) breast tumors, a combination of pertuzumab, trastuzumab, and docetaxel has been effective (59). However, there are still no approved targeted therapies for triple negative ERα−/PR−/HER2− breast tumors (10–17% of all breast cancer cases) (60, 61), or the normal breast-like or basal-like cancer subtype (15% of the cases) (62, 63), which are mostly triple negative and frequently have TP53 mutations (64).

Much attention has been paid to the role of ERRs in breast cancer, as they are orphan nuclear receptors closely related to ERs. ERRα expression in breast tumors is often high, and it is expressed in tumors with poor prognosis (36). In samples from various cohorts of patients with breast cancer, ERRα mRNA positively correlates with the expression of the oncogene ERBB2 and inversely correlates to that of ERα and PR, which are considered as good prognostic markers for patients with breast cancer (36). The expression of ERRα mRNA and protein positively correlates with the coactivator amplified in breast cancer 1 (AIB1), also known as SRC-3 (65). However, ERRα is able to act as both a transcriptional activator and repressor depending on the cellular context, promoting or inhibiting tumor growth in breast cancer (42). In ER− breast cancer cells, ERRα functions as a transcriptional activator constitutively interacting with coactivators and binding to ERRs independently of any ligands. Consequently, ERRα competes with ER in the regulation of estrogen-responsive genes such as the estrogen-regulated trefoil factor 1 (TFF1) (65, 66) and vascular endothelial growth factor (VEGF) (54, 43). In ER+ breast cancer cells, ERRα functions as a transcriptional repressor, interacting with corepressors and binding to negative ERRs (42).

ERRα also plays a role in bone metastasis, which occurs in up to 70% of patients with advanced breast cancer (44). In a mouse xenograft model of metastatic human breast cancer, overexpression of wild-type ERRα-reduced metastasis and breast cancer cell growth in the bone, likely by upregulating the osteoclastogenesis inhibitor, osteoprotegerin (OPG). By contrast, ERRα overexpression increases breast cancer cell growth in the mammary gland and the expression of VEGF. Thus, ERRα plays dual roles, promoting the progression and invasion of primary tumors by decreasing osteolytic lesions in the bone (44).

It has been suggested that the induction of c-myc expression by estrogen occurs through the “non-classical” pathway – without binding of ERα to its promoter (67). Another study demonstrated a positive correlation between ERα, c-myc, and aromatase (37), an enzyme that may enhance estrogen production and stimulate breast cancer progression (38). These studies propose that ERR could play an important role in alternative

---

**TABLE 1 | Expression of ERR isoforms and implication in breast cancer and prostate cancer.**

| Receptor | Breast cancer | Prostate cancer |
|----------|---------------|----------------|
|          | Expression   | Implication             | Reference | Expression | Implication             | Reference |
| ERRα (NR3B1) | High         | Transcriptional activator or repressor | (42)       | High       | Promotion of cell growth | (39)       |
| ERRβ (NR3B2) | Uncertain     | Uncertain               | (34, 38, 43, 44) | Low        | Inhibition of cell growth | (46)       |
| ERRγ (NR3B3) | High/low     | Promotion or inhibition of cell growth | (36, 47, 48) | Low        | Inhibition of cell growth | (49)       |
pathway to classical ERs-dependent pathway in cell signaling through aromatase and c-myc.

ERRα participates in the enhancement of estrogen production by the activation of steroid sulfo transferase (SULT2A1), which maintains high levels of peripheral dehydroepiandrosterone sulfate (DHEAS), an important dehydroepiandrosterone (DHEA) metabolite in estrogen synthesis in certain tissues (68). It has also been reported that SULT2A1 inactivates tamoxifen and raloxifene (69). Thus, SULT2A1 activation by ERRα can partly explain the resistance of breast cancer cells expressing ERRα to SERM therapy.

A clinical study analyzing 102 breast cancer samples revealed that the expression of ERRα in more than 10% of malignant cells was associated with a 20% decrease in overall disease survival at 13 years (70). In this work, association between ERRα and ERE-containing estrogen-responsive genes was markedly altered according to ERRα status in breast cancer tissues, suggesting that ERRα possibly modulates ERα-mediated and ERE-dependent transcription, and changes the expression of estrogen-responsive genes in breast cancer cells. In a previous clinical study, high levels of ERRα mRNA correlated with ERα-tumor status in 38 tumor specimens (36). These two studies suggest that ERRα mRNA and protein expression are associated with an unfavorable prognosis, and increase the risk of recurrence of breast cancer.

ERRγ also acts differently depending on ER expression. In breast tumors co-expressing ER and PR, ERRγ induces E-cadherin expression and promotes the mesenchymal-to-epithelial (MET) transition, resulting in the inhibition of tumor growth (36, 47). It has been shown that an AAAG tetranucleotide polymorphism in the untranslated region of the ERRγ gene is associated with breast cancer predisposition (71), and that ERRγ mediates tamoxifen resistance in invasive lobular breast cancer. In human breast cancer specimens, both ERRγ mRNA and protein expression are upregulated compared with normal samples, and exogenously transfected ERRγ increased breast cancer cell proliferation (36, 48). Tumors overexpressing ERRγ are also frequently steroid receptor positive, which may reflect hormonal sensitivity and a preferable clinical outcome. Thus, ERRγ mRNA expression is associated with a favorable prognosis of patients with breast cancer (36).

ERRβ expression has also been detected in breast tumors. It has been shown that ERRβ expression is associated with that of ERβ, and that ERRβ levels inversely correlate with the S-phase fraction, suggesting that this orphan receptor inhibits cellular proliferation, or possibly promotes cellular differentiation (36). However, another report found that it acts as a proliferative gene (45). Thus, the potential role of ERRβ in breast cancer remains unclear.

ERRs in Prostate Cancer

Prostate cancer, which is dependent on androgens for proliferation and survival, is the second-lead ing cause of cancer-related mortality, after lung cancer, in men from developed countries (72). With early diagnosis, radical prostatectomy and/or radiation therapy are potentially curative. For advanced or metastatic prostate cancer, hormonal therapies, reducing androgen levels by surgical or chemical castration or inhibiting the AR protein by small molecules, are used (57). However, after an initial response, the cancer eventually recurs in an incurable, castration-resistant form (5, 6), as a result of amplification of AR protein, mutations of AR gene, and elevated production of AR variants (73).

In addition to androgen-signaling pathways, estrogen-signaling pathways are implicated in the development of prostate cancer (1), and estrogen has been used for the treatment of advanced prostate cancer (74). The direct effect of estrogens on normal and malignant prostate tissues is assumed to be mediated through ERα and ERβ (75, 76).

ERRα mRNA has been detected in prostate cancer cell lines and human prostate cancer tissue (77). Although a heterogeneous ERRα staining was found in immunohistostaining analysis using prostate cancer tissues with low Gleason score (GS), increased ERRα protein expression was detected in human prostate tissue from 106 surgical resected prostate samples in a study that showed a positive correlation between ERRα expression and GS (78). The enhanced expression of ERRα might play a role in the development of human prostate cancer and serve as a significant prognostic factor for the disease.

By contrast, reduced ERRβ and ERRγ expression in some prostatic carcinomas has been reported (77), and overexpression of ERRβ or ERRγ results in the suppression of cell proliferation in both androgen-sensitive and insensitive prostate cancer cells, suggesting that these receptors present antiproliferative or tumor-suppressing functions in prostate cancer (46, 49). Furthermore, it has been shown that ERRβ directly transactivates a promoter upstream of the cyclin-dependent kinase inhibitor, p21 gene, resulting in the inhibition of the cell cycle progression (46). Clinicopathological studies for the expression of both orphan receptors in human prostate tissues have been performed using immunohistochemical analysis (79). Cancerous lesions and benign foci obtained from radical prostatectomy were stained and immunoreactivity scores (IR scores) were evaluated from the proportion of immunoreactive cells and staining intensity, revealing that ERRβ and ERRγ IR scores are significantly lower in cancerous tissues. In the same study, patients with high ERRα IR score, but low ERRγ IR score, presented a poorer cancer-specific survival when compared to the other group, suggesting that the expression of ERRβ and ERRγ could be a useful prognostic indicator of prostate cancer (79).

ERRs Agonists and Antagonists

Although no endogenous ligands have been identified for these receptors several natural phytoestrogens (three isoflavones: genistein, daidzein, and biochanin A, and one flavone: 6, 3, 4-trihydroxyflavone) have been identified as potential ligands of these receptors with agonistic activities, by structure-based virtual screening and biological functional assays (80, 81). Phytoestrogens are produced by plants, and represent the major natural exogenous sources of estrogenic compounds. DY131 is another ERR agonist, specific to ERRβ and ERRγ that was shown to enhance growth inhibition, which was caused by overexpression
of these nuclear receptors (46, 49). Inhibition of ERα with the inverse agonist XCT790 reduces cell proliferation of various cancer cell lines, including prostate and breast cancer cells (39).

On the other hand, diethylstilbestrol (DB00255) and the tamoxifen metabolite, 4-hydroxytamoxifen, have been shown to interact with ERRβ and ERRγ and act as antagonists (82, 83). SR16388, a novel steroidal antiestrogen, inhibits the interaction between its coactivator peroxisome proliferator-activated receptor γ coactivator-1 α to inhibit ERR α activity (84).

Conclusion

Although the role of orphan nuclear receptors in cancer is becoming clearer as a result of advances in previous studies, their function still remains to be elucidated. A better understanding of ERs in breast and prostate cancer will provide new insights into cancer biology as well as the discovery of novel small molecules that bind to these orphan receptors. This knowledge will be helpful for the identification of novel hormonal therapeutic strategies and cancer treatments.

Acknowledgments

We are grateful to Dr. K. Ikeda (Saitama Medical University) and Dr. K. Horie (Saitama Medical University) for critical reading of this manuscript and helpful suggestions. This work was supported by grants of the Cell Innovation Program and the P-DIRECT from the MEXT, Japan (SI), grants from JSPS, Japan (SI), and a grant of the Program for Promotion of Fundamental Studies in Health Sciences from NIBIO, Japan (SI). This work was supported by grants of the Cell Innovation Program (http://www.cell-innovation.org/) and the P-DIRECT (http://p-direct.mext.go.jp/) from the MEXT, Japan (S.I.), grants from JSPS KAKENHI (Grant Numbers 23249040 and 15K15353), Japan (S.I.), and a grant of the Program for Promotion of Fundamental Studies in Health Sciences from NIBIO (09-12), Japan (S.I.).

References

1. Rouhan-Moniri M, Hsing M, Butler MS, Cherkassov A, Rennie PS. Orphan nuclear receptors as drug targets for the treatment of prostate and breast cancers. Cancer Treat Rev (2014) 40:1137–52. doi:10.1016/j.ctrv.2014.10.005
2. Bonhoff H, Berges R. The evolving role of oestrogens and their receptors in the development and progression of prostate cancer. Eur Urol (2009) 55:533–42. doi:10.1016/j.eururo.2008.10.035
3. Howell SJ, Johnston SR, Howell A. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer. Best Pract Res Clin Endocrinol Metab (2004) 18:47–66. doi:10.1016/j.beem.2003.08.002
4. Smollich M, Gotte M, Fischgrabe J, Radke I, Kiesel L, Wulfing P. Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells. Anticancer Res (2009) 29:2167–71.
5. Egan A, Dong Y, Zhang H, Qi Y, Balk SP, Sartor O. Castration-resistant prostate cancer: adaptive responses in the androgen axis. Cancer Treat Rev (2014) 40:426–33. doi:10.1016/j.ctrv.2013.09.011
6. Lonergan PE, Tindall DJ. Androgen receptor signaling in prostate cancer development and progression. J Carcinog (2011) 10:20. doi:10.4103/1477-3163.83937
7. Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer (2004) 11:643–58. doi:10.1677/erc.0.00776
8. Giguere V. Estrogen-related receptor alpha modulates the expression of adipogenesis-related genes during mouse embryogenesis. Biochim Biophys Acta (1996) 1303:211–23. doi:10.1016/0304-4165(95)01230-5
9. Horard B, Vanacker JM. Estrogen receptor-related receptors: orphan receptors desperately seeking a ligand. J Mol Endocrinol (2003) 31:349–57. doi:10.1677/jme.0.0310349
10. Yang N, Shigeta H, Shi H, Teng CT. Estrogen-related receptor, hERR1, modulates estrogen receptor-mediated response of human lactoferrin gene promoter. J Biol Chem (1996) 271:5795–804. doi:10.1074/jbc.271.10.5795
11. Lauter V, Hanni C, Coll J, Catzeflis F, Stehelin D. Evolution of the nuclear receptor gene superfamily. EMBO J (1992) 11:1003–13.
12. Tora L, Gromemeyer H, Turcotte B, Gaub MP. The N-terminal region of the chicken progesterone receptor specifies target gene activation. Nature (1988) 333:185–8. doi:10.1038/333185a0
13. Warmerk A, Treuter E, Wright AP, Gustafsson JA. Activation functions 1 and 2 of nuclear receptors: molecular strategies for transcriptional activation. Mol Endocrinol (2003) 17:1901–9. doi:10.1210/me.2002-0384
14. Karmakar S, Foster EA, Smith CL. Unique roles of p160 coactivators for regulation of breast cancer cell proliferation and estrogen receptor-alpha transcriptional activity. Endocrinology (2009) 150:1588–96. doi:10.1210/en.2008-1001
15. Liu D, Benlhabib H, Mendelson CR. CAMP enhances estrogen-related receptor alpha (ERα) transcriptional activity at the SP-A promoter by increasing its interaction with protein kinase A and steroid receptor coactivator 2 (SRC-2). Mol Endocrinol (2009) 23:772–83. doi:10.1210/me.2008-0282
16. Skrzypczak M, Kapka-Skrzypczak L, Cyranka M, Trecek O, Wrobel A, Matosiuk D. Nuclear estrogen receptors co-activation mechanisms. Curr Med Chem (2013) 20:3317–38. doi:10.2174/09298673131200999006
17. Treuter E, Albrektsen T, Johansson L, Leers J, Gustafsson JA. A regulatory role for RIP140 in nuclear receptor activation. Mol Endocrinol (1998) 12:864–81. doi:10.1210/med.12.6.0123
18. Pettersson K, Svensson K, Mattsson R, Carlsson B, Ohlsson R, Berkenstam A. Expression of a novel member of estrogen response element-binding nuclear receptors is restricted to the early stages of chorion formation during mouse embryogenesis. Mech Dev (1996) 54:211–23. doi:10.1016/0925-477X(95)00479-3
19. Sladek R, Bader JA, Giguere V. Estrogen-related receptor alpha is a transcriptional regulator of the human medium-chain acyl coenzyme A dehydrogenase gene. Mol Cell Biol (1997) 17:5400–9.
20. Barry JB, Laganiere J, Giguere V. A single nucleotide in an estrogen-related receptor alpha site can dictate mode of binding and peroxisome proliferator-activated receptor gamma coactivator 1alpha activation of target promoters. Mol Endocrinol (2006) 20:302–10. doi:10.1210/en.2005-00313
21. Debois G, Giguere V. Oestrogen-related receptors in breast cancer: control of cellular metabolism and beyond. Nat Rev Cancer (2013) 13:27–36. doi:10.1038/nrc3396
22. Bookout AL, Jeong Y, Downes M, Yu RT, Evans RM, Mangelsdorf DJ. Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell (2006) 126:789–99. doi:10.1016/j.cell.2006.06.049
23. Giguere V. Transcriptional control of energy homeostasis by the estrogen-related receptors. Endocr Rev (2008) 29:677–96. doi:10.1210/er.2008-0017
24. Iijichi N, Ikeda K, Horie-Inoue K, Yagi K, Okazaki Y, Inoue S. Estrogen-related receptor alpha modulates the expression of adipogenesis-related genes during adipocyte differentiation. Biochem Biophys Res Commun (2007) 358:813–8. doi:10.1016/j.bbrc.2007.04.209
25. Kubo M, Iijichi N, Ikeda K, Horie-Inoue K, Takeda S, Inoue S. Modulation of adipogenesis-related gene expression by estrogen-related receptor gamma during adipocytic differentiation. Biochim Biophys Acta (2009) 1789:71–7. doi:10.1016/j.bbadimg.2008.08.012
26. Luo J, Sladek R, Carrier J, Bader JA, Richard D, Giguere V. Reduced fat mass in mice lacking orphan nuclear receptor estrogen-related receptor alpha. Mol Cell Biol (2003) 23:7947–56. doi:10.1128/MCB.23.22.7947-7956.2003
27. Villena JA, Kralli A. ERRalpha: a metabolic function for the oldest orphan. Trends Endocrinol Metab (2008) 19:269–76. doi:10.1016/j.tem.2008.07.005
28. Luo J, Sladek R, Bader JA, Matthyssen A, Rossant J, Giguere V. Placental abnormalities in mouse embryos lacking the orphan nuclear receptor ERR-beta. Nature (1997) 388:778–82. doi:10.1038/42022
Steroid Biochem Mol Biol

and tumor growth of androgen-sensitive and androgen-insensitive prostate
cancer cells and its implication as a therapeutic target for prostate cancer. Cancer
Res (2007) 67:4904–14. doi:10.1158/0008-5472.CAN-06-3855

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer
statistics. CA Cancer J Clin (2011) 61:69–90. doi:10.3322/caac.20107

Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecul-
ar portraits of human breast tumours. Nature (2000) 406:747–52. doi:10.1038/
35021993

Reis-Filho JS, Westbury C, Pierja Y. The impact of expression profiling
on prognostic and predictive testing in breast cancer. J Clin Pathol (2006)
59:225–31. doi:10.1136/jcp.2005.028324

Rouzier R, Wagner P, Morandi P, Pusztai L. Gene expression profiling of
primary breast cancer. Curr Oncol Rep (2007) 9:38–44. doi:10.1007/s11912-005-
0024-y

Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene
expression patterns of breast carcinomas distinguish tumor subclasses with
clinical implications. Proc Natl Acad Sci U A (2001) 98:10869–74. doi:10.1073/
pnas.981367098

Anderson WF, Chatterjee N, Ershiller WB, Brawley OW. Estrogen recep-
tors in breast cancer phenotypes in the surveillance, epidemiology, and end
results database. Breast Cancer Res Treat (2002) 76:27–36. doi:10.1023/A:
1020299707510

Niemeyer LA, Dabb JS, Berivial S, Strebil MB, Bhargava R. Androgen receptor
in breast cancer: expression in estrogen receptor-positive tumors and in estro-
gen receptor-negative tumors with apocrine differentiation. Mod Pathol (2010)
23:205–12. doi:10.1038/modpathol.2009.159

Damber JE, Mur G. Prostate cancer. Lancet (2008) 371:1710–21. doi:10.1016/
S0140-6736(08)60729-1

Mohamed A, Krajeski K, Cakar B, Ma CX. Targeted therapy for breast cancer.
Am J Pathol (2013) 183:1096–112. doi:10.1016/j.ajpath.2013.07.005

Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, et al. Per-
tuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast
cancer. N Engl J Med (2013) 372:724–34. doi:10.1056/NEJMoa1413513

Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis
of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and
HER2-negative invasive breast cancer, the so-called triple-negative phenotype:
a population-based study from the California Cancer Registry. Cancer (2007)
109:1721–8. doi:10.1002/cncr.22618

Crisciello C, Azim HA Jr, Schouten PC, Linn SC, Sotiriou C. Understanding
the biology of triple-negative breast cancer. Ann Oncol (2012) 23(Suppl
6):vi13–8. doi:10.1093/annonc/mds188

Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology
(2008) 52:108–18. doi:10.1111/j.1365-2559.2007.02889.x

Cancer Genome Atlas Network. Comprehensive molecular portraits of human
breast tumours. Nature (2012) 490:61–70. doi:10.1038/nature11412

Perou CM. Molecular stratification of triple-negative breast cancers. Oncologist
(2011) 16(Suppl 1):61–70. doi:10.1634/theoncologist.2011-S1-61

Heck S, Rom J, Thewes V, Becker N, Blume B, Sinn HP, et al. Estrogen-related
receptor alpha expression and function is associated with the transcriptional
coregulator AIIB1 in breast carcinoma. Cancer Res (2009) 69:5186–93. doi:
10.1158/0008-5472.CAN-08-3062

Surowiak P, Materna V, Gyorffy B, Matkowski R, Wojnar A, Maciejczyk A,
et al. Multivariate analysis of oestrogen receptor alpha, pS2, metallothionein
and CD24 expression in invasive breast cancers. Br J Cancer (2006) 95:339–46.
doi:10.1038/sj.bjc.6603254

DeNardo DG, Cuha VL, Kim H, Wu K, Lee AV, Brown PH. Estrogen receptor
DNA binding is not required for estrogen-induced breast cell growth. Mol Cell
Endocrinol (2007) 277:13–25. doi:10.1016/j.mce.2007.07.006

Seely J, Amigh KS, Suzuki T, Maybaw B, Sasano H, Giguere V, et al. Tran-
scriptional regulation of dehydroepiandrosterone sulfotransferase (SULT2A1)
by estrogen-related receptor alpha. Endocrinology (2005) 146:3665–13. doi:
10.1210/en.2004-1619

Apak TI, Dufell MW. Interactions of the stereoisomers of alpha-
hydroxytioxemoxifen with human hydroxydroxysterol sulfotransferase SULT2A1
and rat hydroxydrosyrustol sulfotransferase SIA. Drug Metab Dispos (2004)
32:1501–8. doi:10.1124/dmd.104.000991

Suzuki T, Miki Y, Moriya T, Shimada N, Ishida T, Hirakawa H, et al. Estrogen-
related receptor alpha in human breast carcinoma as a potent prognostic
factor. Cancer Res (2004) 64:4670–6. doi:10.1158/0008-5472.CAN-04-0250
Differential expression of estrogen-related receptors beta and gamma (ERRbeta and ERRgamma) and their clinical significance in human prostate cancer. *Cancer Sci* (2010) **101**:646–51. doi:10.1111/j.1349-7006.2009.01451.x

80. Suetsugi M, Su L, Karlsberg K, Yuan YC, Chen S. Flavone and isoflavone phytoestrogens are agonists of estrogen-related receptors. *Mol Cancer Res* (2003) **1**:981–91.

81. Tremblay GB, Kunath T, Bergeron D, Lapointe L, Champigny C, Bader JA, et al. Diethylstilbestrol regulates trophoblast stem cell differentiation as a ligand of orphan nuclear receptor ERR beta. *Genes Dev* (2001) **15**:833–8. doi:10.1101/gad.873401

82. Coward P, Lee D, Hull MV, Lehnmann JM. 4-Hydroxytamoxifen binds to and deactivates the estrogen-related receptor gamma. *Proc Natl Acad Sci U S A* (2001) **98**(15):8880–4. doi:10.1073/pnas.151244398

83. Tremblay GB, Bergeron D, Giguere V. 4-Hydroxytamoxifen is an isoform-specific inhibitor of orphan estrogen-receptor-related (ERR) nuclear receptors beta and gamma. *Endocrinology* (2001) **142**(10):4572–5. doi:10.1210/en.142.10.4572

84. Chao WR, Amin K, Shi Y, Hobbs P, Tanabe M, Tanga M, et al. SR16388: a steroidal antiangiogenic agent with potent inhibitory effect on tumor growth in vivo. *Angiogenesis* (2011) **14**(1):1–16. doi:10.1007/s10456-010-9191-z

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2015 Misawa and Inoue. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.